Status:
ACTIVE_NOT_RECRUITING
Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Neovascular Age-Related Macular Degeneration (nAMD)
Treatment-naïve
Eligibility:
All Genders
50+ years
Brief Summary
Neovascular Age-Related Macular Degeneration (nAMD) is a one of the leading causes of irreversible vision loss among the elderly in developed countries. The implementation of anti-VEGF therapies in th...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Age of 50 years or older
- Treatment-naïve patients diagnosed with nAMD who have received a loading dose with intravitreal faricimab
- Follow-up data available until the next subsequent faricimab injection after the loading dose, OR if no injections were indicated following the loading dose, follow-up data for at least 4 months
- Exclusion criteria
- History of previous anti-VEGF treatment.
- Neovascular conditions other than AMD (e.g., choroidal neovascularization due to other causes) or co-existence of other retinal disease in the study eye
- Intraocular surgery in the study eye during the loading dose or prior to the first follow-up visit after the loading dose.
Exclusion
Key Trial Info
Start Date :
November 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2026
Estimated Enrollment :
828 Patients enrolled
Trial Details
Trial ID
NCT06890026
Start Date
November 15 2024
End Date
February 1 2026
Last Update
December 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Rigshospitalet
Glostrup Municipality, Denmark, 2600